LONDON--(BUSINESS WIRE)--Technavio’s latest market research report on the global ENT disorder treatment market provides an analysis on the most important trends expected to impact the market outlook from 2017-2021. Technavio defines an emerging trend as a factor that has the potential to significantly impact the market and contribute to its growth or decline.
Sapna Jha, a lead analyst from Technavio, specializing in research on cardiovascular and metabolic disorders sector says, “The ENT disorder treatment market is expected to benefit from the highly generic nature of the disorders and will grow because of the deteriorating nature of the environment. Rhinitis is one of the most prevalent ENT disorders and has been affecting a large number of people across the world.”
Looking for more information on this market? Request a free sample report
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
The top three emerging market trends driving the global ENT disorder treatment market according to Technavio research analysts are:
- Growing consolidation in industry particularly for rhinitis
- Increase in research on allergic disorders
- Awareness about controlled usage of antibiotics
Growing consolidation in industry particularly for rhinitis
There is growing consolidation in the ENT disorder treatment market. For instance, in 2014, Novartis and GSK agreed to re-align their product offerings to focus on their respective core strengths. Such consolidations help to avoid unnecessary competition, which in turn, helps the market to grow.
Rhinitis is expected to hold 70%-80% of total ENT drug pipeline. The rising prevalence of allergic diseases, especially rhinitis, has motivated companies to invest in the segment and this is expected to drive the market in the coming years. Some of the major companies such as GSK and Merck are showing strong potential in the allergic rhinitis market, owing to their strong pipeline.
Increase in research on allergic disorders
The Australasian Society of Clinical Immunology and Allergy, Allergy and Anaphylaxis Australia, and the European Academy of Allergy and Clinical Immunology are working for a better understanding of allergic diseases. So much so, that allergic disorders are increasingly being considered as major public health threats.
“Environmental deterioration and lifestyle changes brought about by urbanization are triggering allergic diseases. These factors are driving the need for prioritization on R&D in the field of allergic disorders,” says Sapna.
The burgeoning R&D pipeline of immunotherapy predicts its rapid growth in the coming times. For instance, ALK has five distinct sublingual immunotherapy tablets under clinical development. Most of the key vendors of the market such as GSK and Sanofi are working on their pipeline to introduce drugs for allergic diseases such as allergic rhinitis.
Awareness about controlled usage of antibiotics
Antibiotic resistance is one of the major problems being faced by the medical world today. It can be defined as an occasion when a microorganism changes itself and no longer remains sensitive to that particular antibiotic, as a result of which, the antibiotic is no longer capable of killing or inhibiting the growth of the bacteria.
Antibiotic resistance leads to several other problems such as longer treatment regimens, longer hospitalizations, and increased side effects. This leads to enormous burdens on the healthcare system, using significant economic and human resources. Many global organizations are working to raise awareness about the excess usage of antibiotics. For instance, the WHO launched a campaign for the reduction of antibiotic usage from 14-20 November 2016.
Browse Related Reports:
- Global Neutropenia Treatment Market 2017-2021
- Global Swine Health Market 2017-2021
- Global Botanical and Plant-Derived Drugs Market 2017-2021
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like oncology, vaccines, and urology devices. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, re-sellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
